AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

CERT · NASDAQ · Medical - Healthcare Information Services

Certara (CERT)

Supports drug-development decisions with biosimulation software, scientific technology, and services.

$8.87

After hours+0.03 (+0.35%)

At close$8.84(+3.76%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	86	88	97	93	95	100	106	105	105	104	107	93
Cost of revenue	36	34	39	40	37	38	42	41	40	39	56	35
Gross profit	50	54	57	54	58	62	64	64	65	64	51	58
	102	62	59	63	55	56	57	54	62	64	47	58
Research & development	9	8	12	9	8	8	11	9	10	11	12	10
	35	42	34	40	33	34	32	31	38	38	43	37
Selling & marketing	7	9	11	12	11	13	13	14	13	14	13	15
General & administrative	28	34	23	28	22	21	20	17	25	24	29	22
Other expenses	59	12	13	13	13	14	14	14	14	14	−8	12
Operating income	−53	−8	−1	−9	3	6	8	10	3	1	4	0
	−1	−4	−4	−3	−4	−4	−3	−3	−3	−4	−12	−6
Interest expense	6	6	6	6	5	5	5	5	5	34	5	−5
Other non-operating income	−5	−2	−2	−2	9	−1	−2	−2	−2	−31	7	1
Income before tax	−54	−12	−5	−12	−2	2	5	6	0	−3	−8	−6
Income tax expense	−5	0	−1	0	0	−4	0	8	−2	3	1	0
Net income from continuing operations	−49	−12	−5	−13	−1	7	5	−2	2	−6	−9	−6
Discontinued operations	0	0	0	0	0	0	0	0	0	0	0	−49
Net income	−49	−12	−5	−13	−1	7	5	−2	2	−6	−9	−55
EPS, basic	−$0.31	−$0.08	−$0.03	−$0.08	−$0.01	$0.04	$0.03	−$0.01	$0.01	−$0.04	−$0.06	−$0.36
EPS, diluted	−$0.31	−$0.08	−$0.03	−$0.08	−$0.01	$0.04	$0.03	−$0.01	$0.01	−$0.04	−$0.06	−$0.36
Weighted average shares, basic	159	159	160	161	161	161	161	161	160	160	158	154
Weighted average shares, diluted	159	159	160	161	161	161	161	161	161	160	158	154
EBITDA	−34	8	17	10	−6	25	28	30	23	32	16	12
Depreciation & amortization	14	15	16	17	0	18	19	19	19	0	19	13
EBIT	−48	−7	0	−7	−7	7	9	11	5	31	−3	−1